CF PharmTech (HKG:2652) said Chinese regulators had accepted its marketing authorization application for tiotropium bromide inhalation powder for review, according to a Tuesday filing with the Hong Kong bourse.
The product is designed to treat bronchospasm associated with chronic obstructive pulmonary disease and help keep reduce exacerbations associated with the condition.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.